Iluvien receives Priority Review

FDA accepted for filing and granted Priority Review to an NDA from Alimera Sciences Inc. (NASDAQ:ALIM) for Iluvien to treat diabetic macular edema (DME). The company expects a decision in 4Q10. In Jul...